MindMaze Therapeutics Holding (XSWX:MMTX) Treasury Stock: CHF-0.15 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.16
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Treasury Stock?

MindMaze Therapeutics Holding XSWX:MMTX +3.67% 4 Treasury Stock is CHF-0.15 Mil as of Dec. 2025. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. MindMaze Therapeutics Holding's treasury stock for the quarter that ended in Dec. 2025 was CHF-0.15 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

MindMaze Therapeutics Holding Treasury Stock Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Treasury Stock Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Treasury Stock
-0.15 -0.15

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Treasury Stock -0.15 -0.15
XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of CHF-0.15 Mil mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Treasury Stock of CHF-0.15 Mil as of Dec. 2025. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Treasury Stock too high?
MindMaze Therapeutics Holding's current Treasury Stock is CHF-0.15 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Treasury Stock compare to VRTX and REGN?
MindMaze Therapeutics Holding's Treasury Stock of CHF-0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Treasury Stock is CHF-0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Treasury Stock of CHF-0.15 Mil. The current Treasury Stock is CHF-0.15 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Treasury Stock is CHF-0.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.16
Price